About teclistamab
Bispecific BCMA-directed T-cell engager antibody
Used for
- Treats adults with relapsed or refractory multiple myeloma after several prior treatments.
Usual adult dose
Given under the skin using step-up doses, then usually once weekly; schedules may change with response.
Common side effects
- Cytokine release syndrome
- Infections
- Low blood cell counts
- Nervous system effects, including confusion or headache
Important warnings
- Step-up doses require close monitoring for cytokine release syndrome.
- Serious infections and low blood counts can occur.
- Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, can occur.
- Can cause harm to an unborn baby; effective contraception is needed during treatment and for five months afterward.
Pregnancy
May cause fetal harm. Use effective contraception during treatment and for five months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for five months after the last dose.
Interactions
- May alter the effects of some CYP450-metabolized medicines, especially around treatment initiation and cytokine release syndrome.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.